A5027432260- Vasculitis and related conditions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Myasthenia Gravis and Thymoma
- Inflammatory Bowel Disease
- Microscopic Colitis
- Otitis Media and Relapsing Polychondritis
- Head and Neck Surgical Oncology
- Hemophilia Treatment and Research
- Parkinson's Disease and Spinal Disorders
- Heparin-Induced Thrombocytopenia and Thrombosis
- Renal Diseases and Glomerulopathies
- Pituitary Gland Disorders and Treatments
- Pregnancy and Medication Impact
- Systemic Lupus Erythematosus Research
- Ear and Head Tumors
- Translation Studies and Practices
- Urticaria and Related Conditions
- Rheumatoid Arthritis Research and Therapies
- Neuroendocrine Tumor Research Advances
- Sympathectomy and Hyperhidrosis Treatments
Aarhus University Hospital
2021-2024
Central Denmark Region
2024
Aarhus University
2024
University of Southern Denmark
2024
To explore current management practices for PMR by general practitioners (GPs) and rheumatologists including implications clinical trial recruitment.An English language questionnaire was constructed a working group of GPs from six countries. The focused on: 1: Respondent characteristics; 2: Referral practices; 3: Treatment with glucocorticoids; 4: Diagnostics; 5: Comorbidities; 6: Barriers to research. distributed worldwide via members the International PMR/Giant Cell Arteritis Study...
Following the approval of tocilizumab (TCZ) for giant cell arteritis (GCA), recent studies have shown a high relapse frequency after abrupt discontinuation TCZ. However, thorough exploration TCZ tapering compared to has never been undertaken. Likewise, adverse events only scarcely investigated in routine care. This study aimed compare incidence relapses GCA patients undergoing discontinuation.
Background In myasthenia gravis (MG), first-line treatment for MG is acetylcholinesterase inhibitors which alleviates symptoms, but concomitantly may cause autonomic adverse effects. Aims of the study this study, we evaluated if symptoms overactive bladder (OAB) are more frequent among patients than healthy controls. Methods Eighty-three and 50 sex- age-matched controls were included answered questionnaire "International Consultation on Incontinence Questionnaire Overactive Bladder Module"...
Low socioeconomic status is associated with disadvantages in health outcomes and delivery of medical care patients Inflammatory Bowel Disease (IBD). Inequality the utilisation biologic treatment largely unexplored.
The DANIsh VASculitis cohort study, DANIVAS, is an observational national multicenter study with the overall aim to prospectively collect protocolized clinical data and biobank material from patients polymyalgia rheumatica (PMR) giant cell arteritis (GCA) diagnosed and/or followed at Danish rheumatology departments. A long-term key objective investigate whether use of new clinically implemented diagnostic imaging modalities facilitates disease stratification in GCA-PMR spectrum. In...
Journal Article Accepted manuscript Comment on: "Real-world outcomes of a dedicated fast-track polymyalgia rheumatica clinic" Get access Agnete Overgaard Donskov, Donskov Department Rheumatology, Aarhus University Hospital, Central Denmark Region, Aarhus, DenmarkDepartment Clinical Medicine, University, Health, Corresponding author details: Postal address: Palle Juul Jensen Boulevard 59, 8200 N, Denmark. Email agnead@rm.dk https://orcid.org/0000-0002-7909-1624 Search for other works by this...
Myasthenia Gravis (MG) is characterised by muscle weakness and increased fatigability. The aim of this pilot study was to investigate if patients with MG demonstrate different functional chewing patterns report more complaints related mastication as compared healthy controls. Twelve (median 60 years Q1–Q3: 46–70) generalised nine controls 57 55–63) participated. All participants underwent dental oral examination were asked fill in a questionnaire concerning health. Static maximum bite force...
Background In most countries polymyalgia rheumatica (PMR) is diagnosed and managed by both general practitioners (GP) rheumatologists. However, the referral pattern from GP’s to specialist around world has not been described. The initial prednisolone dose recommended EULAR/ACR between 12.5 25 mg 1 , but little known about whether these guidelines are followed everywhere in clinical practice 2 . Objectives This study aims describe refererral treatment strategy for PMR several worldwide....
Background Polymyalgia rheumatica (PMR) is diagnosed and treated by both general practitioners (GP) rheumatologists. How rheumatologists around the world manage referral process of patients with PMR from GP’s has not been described. EULAR/ACR guidelines recommend initial prednisolone doses between 12.5 25 mg, but it unknown if are followed in daily clinical practice 1 . In addition, understanding challenges for recruitment to trials currently limited. Objectives This study aims describe...